2 lectures · 116 items
Global guideline on the use of GLP-1 medicines in treating obesity issued by WHO
EU Launches Ambitious "Safe Hearts Plan": A New Roadmap in Cardiovascular Health
GPcardio and ACC’s NCD Academy Join Forces to Strengthen Primary Care in Cardiovascular Disease Prevention
Global Shift: From Underweight to Obesity Dominance in Three Decades Across Generations
Slides | Take home messages of EPCCS Guidance on 'Current management of diabetes and CV risk in primary care'
Шляхи стимулювання модифікації способу життя з метою зменшення серцево-судинного ризику на первинній ланці медичної допомоги
Stimulating health behaviour changes to reduce cardiovascular risk in primary careretatrutide yields up to 18.8 percent weight loss and a 10.8 mmHg lower systolic blood pressure in obesity with type 2 diabetes, with hypotension and dysesthesia as new signals
Presented at EASD 2026 in Milan and published simultaneously in The Lancet. TRIUMPH-2 randomised 1,152 adults with obesity or overweight (BMI 27 or higher, mean 38.2) and type 2 diabetes (mean HbA1c…
synergy between cardiac and extracardiac mechanisms and effects of novel therapies.
This narrative review frames heart failure with preserved ejection fraction (HFpEF) as a systemic disease driven by the convergence of obesity, type 2 diabetes, and chronic kidney disease, which…
retatrutide monotherapy lowers HbA1c by up to 1.1 percentage points more than placebo and body weight by up to 15 percent
Phase 3, double-blind trial in 537 adults with type 2 diabetes inadequately controlled on diet and exercise (mean HbA1c 7.9 percent, BMI 35.8, diabetes duration 2.5 years), randomised to once-weekly…
Chronic kidney disease is driven by a pro-inflammatory state that accelerates both renal decline and major cardiovascular events. This review outlines key inflammatory pathways and highlights…
This narrative review evaluates pharmacological strategies for preventing type 2 diabetes in individuals with obesity and insulin resistance. While metformin retains the strongest long-term evidence…
A Review.
A recent narrative review and phase 3 trial data (SURMOUNT-OSA) demonstrate that GLP-1 receptor agonists, including tirzepatide, reduce the apnea-hypopnea index by 20 to 24 events per hour in adults…
In a large retrospective target trial emulation using electronic health records, initiation of GLP-1 receptor agonists versus SGLT2 inhibitors was associated with significantly lower 4-year all-cause…
A Prespecified Secondary Analysis.
In a prespecified secondary analysis of the SELECT trial, researchers evaluated the effect of semaglutide on high-sensitivity C-reactive protein (hsCRP) in 17,604 patients with established…
Translating Evidence into Clinical Practice.
Chronic kidney disease in type 2 diabetes affects 30–40% of patients and substantially increases cardiovascular risk and mortality. Recent evidence supports the simultaneous use of SGLT2 inhibitors…
A systematic review and meta-analysis.
A meta-analysis of 32 RCTs (47,332 participants) compared the blood pressure-related safety profiles of tirzepatide and semaglutide in patients with type 2 diabetes or obesity. Tirzepatide…
Sex-Specific Insights Across the Continuum from Diagnosis to Outcomes.
This narrative review examines sex-specific differences in the pathophysiology, diagnostic challenges, and therapeutic responses of heart failure with preserved ejection fraction (HFpEF) in women…
This narrative review evaluates the pharmacological and clinical advances of combination therapies using peptide hormone co-agonists, such as GLP-1 combined with FGF21 or GDF15 analogs, for chronic…
